Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

Medical experts discuss the evolving treatment landscape and adverse events associated with 3L colorectal cancer treatment.

Funding supported by Taiho Oncology. Content independently developed by OncLive.

EP. 1: Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

March 28th 2024

John Strickler, MD, introduces a panel of medical experts who will provide key insights for considerations in the 3L colorectal cancer treatment setting.

EP. 2: Selecting Optimal 3L Colorectal Cancer Treatment

March 28th 2024

Arvind Dasari, MD, MS, illustrates pivotal points of emphasis in choosing the appropriate treatment strategy for a patient receiving 3L treatment for colorectal cancer.

EP. 3: Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

April 4th 2024

Medical experts dissect the first patient-specific case and corresponding treatment regimen.

EP. 4: General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

April 4th 2024

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.

EP. 5: Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

April 11th 2024

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.

EP. 6: Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

April 11th 2024

John Strickler, MD, presents the case of a 62-year-old woman with rectal cancer, and Arvind N. Dasari, MD, MS, provides clinical insights on his approach to third-line treatment with regorafenib, highlighting dose strategy and patient education.

EP. 7: Treatment Considerations With Regorafenib in Colorectal Cancer

April 18th 2024

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

EP. 8: Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

April 18th 2024

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

EP. 9: FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

April 25th 2024

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

EP. 10: Monitoring and AE Management Strategies with Fruquintinib in CRC

April 25th 2024

Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib.